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ABSTRACT 
Background. β1,3 galactosyltransferase (B3GALT5) is responsible for the 
synthesis of type 1 chain oligosaccharides, including Lewis antigens as 
sialyl-Lewis a, the epitope of tumor marker CA19.9 and an E-selectin ligand 
potentially involved in cancer malignancy. Transcription occurs through 
multiple promoters. In some epithelia it is driven by a weak promoter, 
known as the native promoter that is epigenetically modulated and sensitive 
to nuclear factor NF-Y. In some organs of the gastrointestinal tract (as the 
colon, stomach, pancreas and related cell lines) another stronger promoter 
is active and named the LTR promoter after its retroviral origin. It was 
supposed to be regulated through a set of homeoproteins: hepatocyte 
nuclear factor HNF1α/β and caudal-related homeobox Cdx1/2. Surprisingly, 
B3GALT5 is strongly down regulated in colon cancer, the LTR transcript is 
not relevant in the small intestine, and Cdx1/2 were reported absent from a 
cell line expressing large amount of such transcript. 
Aims. To elucidate the mechanisms controlling transcription of B3GALT5 
through its retroviral LTR promoter, in order to explain the tissue specificity 
and down-regulation in colon adenocarcinomas, and to understand the 
evolutionary stabilization of the transposon in some primates. 
Methods. To this aim, we determined the expression levels of putative 
transcription factors by western blot and the amounts of B3GALT5 LTR 
transcript by competitive RT-PCR in cancer tissues and cell lines. 
Moreover, we silenced HNF1α or β in different cell lines, through an shRNA 
approach, expressed them in another by permanent cDNA transfection, 
and treated cells with the DNA demethylating agent 5’-AZA-2’-
deoxycitydine and in all cases, we measure the effects on LTR transcript 
levels. We also evaluated the behavior of the LTR promoter in vitro, 
through electrophoresis mobility shift and reporter luciferase assays. 
Abstract 
II 
 
Results. We found that Cdx1/2 are not detectable in cells and tissues 
expressing high amount of B3GALT5 LTR transcript, while HNF1α/β are 
well detectable, but even in cells and cancers expressing very low or 
undetectable levels of the transcript, which is absent in all cells lacking 
HNF1α/β. Among them, the cell line MDA-MB-231, upon transfection with 
HNF1α or β, became able to express B3GALT5 LTR transcript, but a very 
low levels, similar to those found in colon cancers. Transient silencing of 
HNF1α in cells expressing both HNF1α and β, has no effect on LTR 
transcript, while similar silencing of HNF1β in cells expressing HNF1β only, 
determines strong reduction of the transcript. Cell lines expressing high 
levels of B3GALT5 LTR transcript are affected by the demethylating agent 
5AZA that determines strong down regulation of the transcript, falling down 
to the amounts found in colon cancers, while HNF1 levels remain 
unaffected. In vitro, luciferase placed under the control of LTR promoter is 
more active in cells or clones expressing high HNF1 and low or no LTR 
transcript than in those expressing low HNF1 and high transcript. The same 
promoter, when used as a probe in EMSA, forms specific complex with 
nuclear protein extracted from all cells expressing HNF1, irrespectively of 
the levels of B3GALT5 LTR transcript.  
Conclusion. Our results suggest that HNF1α and HNF1β are necessary 
but not sufficient to drive expression of LTR promoter, while Cdx1/2 are not 
involved. HNF1/β play an interchangeable and not cumulative role and are 
not immediately responsible for cancer down-regulation, which depends on 
a distal regulatory element(s) active when methylated. The successful 
insertion and activation of B3GALT5 LTR promoter during evolution 
depended not only on its HNF1 binding site, but even on such distal 
element(s) unknown at present. 
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RIASSUNTO 
Introduzione. La β1,3 galattosiltransferasi (B3GALT5) è responsabile della 
sintesi della catena oligosaccaridica di tipo 1, tra cui gli antigeni Lewis 
come il sialil-Lewis a, epitope del marcatore tumorale CA19.9 e ligando 
della E-selectina, potenzialmente coinvolto nella malignità tumorale. La sua 
trascrizione è regolata da molteplici promotori. In alcuni epiteli essa è sotto 
il controllo di un promotore debole, chiamato nativo, modulato 
epigeneticamente e tramite il fattore nucleare NF-Y. In alcuni organi e 
cellule di origine gastrointestinale è attivo inoltre un altro promotore, più 
forte e chiamato LTR per la sua origine retrovirale, che secondo la 
letteratura dovrebbe essere regolato attraverso il fattore nucleare 
epatocitario HNF1α/β e quello analogo al Caudale di drosofila Cdx1/2. 
Tuttavia la B3GALT5 è repressa nel cancro del colon, il trascritto LTR non 
è rilevante nell’intestino tenue, e Cdx1/2 risultano assenti in una linea 
cellulare che esprime grandi quantità di tale trascritto. 
Scopi. Scoprire i meccanismi che controllano la trascrizione di B3GALT5 
attraverso il suo promotore LTR, con l’obiettivo di spiegare la specificità 
tissutale e la repressione negli adenocarcinomi del colon, nonché di capire 
il processo di stabilizzazione evolutiva del trasposone in alcuni primati.      
Metodi. A questo scopo abbiamo quantificato l’espressione di HNF1α/β e 
Cdx1/2, tramite Western Blot, e quella del trascritto B3GALT5 LTR, tramite 
RT-PCR competitiva, in tessuti tumorali e linee cellulari. Inoltre, abbiamo 
silenziato HNF1α o β in diverse cellule, tramite shRNA, e li abbiamo 
espressi in un’altra, tramite trasfezione del cDNA. Abbiamo quindi trattato 
delle cellule con l'agente demetilante il DNA 5'-AZA-2'-desossicitidina, 
misurandone poi i livelli di trascritto LTR. Abbiamo infine valutato il 
promotore LTR in vitro, mediante saggi di EMSA e di luciferasi.      
Risultati. Cdx1/2 risultano immisurabili in cellule e tessuti che pur 
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esprimono alti livelli di trascritto LTR, mentre HNF1α/β sono presenti anche 
in cellule e tumori che esprimono una quantità bassa o nulla del trascritto. 
Nelle cellule che non esprimono HNF1α/β però non c’è espressione alcuna 
del trascritto LTR. Tra queste, le MDA-MB-231, dopo transfezione con 
HNF1α o β, esprimono il trascritto LTR, ma a bassi livelli, paragonabili a 
quelli dei tumori del colon. Il silenziamento di HNF1α in una linea cellulare 
che esprime entrambi i fattori HNF1α e β non ha effetti nell’espressione del 
trascritto LTR, mentre quello di HNF1β in un’altra linea che esprime solo 
HNF1β produce forte riduzione del trascritto. Pure il trattamento con 5'-
AZA-2'-desossicitidina riduce il trascritto in cellule che ne esprimono alti 
livelli, portandolo ai livelli dei tumori del colon, e senza effetto sulla quantità 
di HNF1. Usando i saggi delle luciferasi, abbiamo visto che la luciferasi 
sotto il controllo del promotore LTR è più attiva in cellule e cloni che 
esprimono alte quantità di HNF1, anche se non esprimono o esprimono 
poco trascritto LTR, che in quelle cellule che esprimono poco HNF1 ma 
magari una grande quantità di trascritto. Usando la sequenza del 
promotore LTR in saggi di EMSA, abbiamo visto che forma dei complessi 
specifici con estratti di proteine nucleari di tutte le linee cellulari che 
esprimono HNF1, indipendentemente dei livelli di espressione del trascritto 
B3GALT5 LTR.  
Conclusione. I nostri risultati suggeriscono che HNF1α e -β sono 
necessari ma non sufficienti a regolare l'espressione del promotore LTR, 
mentre Cdx1/2 non sono coinvolti. HNF1/β svolgono un ruolo 
intercambiabile e non cumulativo, e non sono immediatamente responsabili 
della regolazione negativa che avviene nel cancro, che invece dipende da 
elementi regolatori distanti attivi solo se metilati. Il successo della 
inserzione e l'attivazione del promotore B3GALT5 LTR durante l'evoluzione 
dipendono quindi non solo dal suo sito di legame a HNF1, ma anche da 
questi elementi distanti attualmente sconosciuti.   
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B3GALT5 gene codes for β1,3 galactosyltransferase 5 (B3GALT5), an 
enzyme responsible for the synthesis of type 1 chain carbohydrates in 
mammals. In humans, in particular, it participates in the biosynthesis of the 
histo-blood group antigens Lewis a (Le(a)), Lewis b (Le(b)) and sialyl-Lewis 
A (sLe(a)) [1]. sLe(a) is the tetrasaccharide antigenic epitope (NeuAcα2-
3Galβ1-3[Fucα1-4]GlcNAc) that constitutes the epitope of CA19.9 antigen 
[2, 3], a tumor marker widely used in the clinical practice.  
1.1 B3GALT5 in the biosynthesis of Lewis-type antigens 
At least four glycosyltransferases are required for the synthesis of the 
sLe(a) epitope (Figure 1.1). First, one of the N-
acetylglucosaminyltransferase enzymes catalyses the addition of N-
acetylglucosamine (GlcNAc) to N- or O-linked chains [4] of glycoproteins, or 
even to glycolipids [5]. After that, N-acetylglucosamine-β1,3-
galactosyltransferase (B3GALTs) transfers a galactose (Gal) to GlcNAc 
with a β1,3-linkage, resulting in the synthesis of the type 1 chain, Galβ1-
3GlcNAc (lacto-N-biose), and then one of Galactose-α2,3-sialyltransferases 
(ST3GALTs) transfers sialic acid to the Gal residue of the type 1 chain with 
an α2,3- linkage, resulting in the synthesis of sialyl-type 1 chain, NeuAc-α2-
3Galβ1-3GlcNAc (sialyl-lacto-N-biose). Finally, α1,3/4-fucosyltransferase 
(FUTIII) transfers fucose (Fuc) to the GlcNAc residue of the sialyl-type 1 
chain with an α1,4-linkage to complete the structure NeuAc-α2-3Galβ1-
3[Fucα1-4]GlcNAc. Le(a) and Le(b) antigens are originated by the mono- or 
di- fucosyl substitution of lacto-N-biose, respectively. 
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Figure 1.1 Biosynthetic pathway and structures of Lewis-type antigens. 
Substitution of GlcNAc by a β1,3-linked galactose leads to lacto-N-biose, 
the basic unit of type 1 chain, while substitution with a β1,4-linked galactose 
leads to N-acetyllactosamine (LacNAc), the basic unit of type 2 chain. The 
addition of a fucose linked either via α1,4 or α1,3 to N-acetylglucosamine in 
type 1 or 2 chains respectively, leads to the formation of Le(a) and Le(x), 
respectively. These antigens can be further elongated by a α1,2 fucose, 
leading to the formation of Le(b) and Le(y) antigens, respectively. The α2,3-
sialylation of type 1 or 2 chains, followed by the addition of α1,4- or α1,3-
linked fucose, respectively, leads to the biosynthesis of sialyl Le(a) and 
sialyl Le(x) antigens, respectively. 
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The first cloning of a B3GALT gene was performed in 1996 starting from 
human WM266–4 melanoma cells and using an expression cloning 
approach [6]. Later on, three putatively novel human B3GALT genes 
homologous to the original one were cloned [7, 8]. Such B3GALTs were 
named B3GALT1 to -T4 [8]. Expression studies on the four human 
B3GALTs demonstrated that two of them, B3GALT1 and T2, transfer Gal to 
GlcNAc in a β1,3-linkage, resulting in type 1 chain synthesis, while 
B3GALT4 transfers Gal to an N-acetylgalactosamine (GalNAc) residue, 
resulting in the synthesis of the type 3 chain, Galβ1-3GalNAc [8]. The 
activity of human B3GALT3 has not been detected toward any of the 
acceptor substrates used [8]. The tissue distribution of the four B3GALTs 
was determined by Northern analysis [7, 8], and it was found that neither 
B3GALT1 nor -T2 is expressed in the pancreas, which indicated that there 
was at least another unknown B3GALT synthesizing the type 1 chain in the 
pancreas. In 1999, the B3GALT5 cDNA was first cloned from the human 
colon adenocarcinoma cell line COLO-205 by Isshiki et al., and the enzyme 
was proposed as the most probable candidate participating in the synthesis 
of the sLe(a) epitope in gastrointestinal and pancreatic cells [1].  
1.2. Role of Sialyl Lewis antigens 
Substitution of GlcNAc by a β1,4-linked galactose (instead of a β1,3-linked 
galactose) leads to LacNAc, the basic unit of type 2 chains. The α2,3-
sialylation of type 2 chain, followed by the addition of α1,3-linked fucose, 
leads to the biosynthesis of sialyl Lewis x (sLe(x)) antigen [9]. An aberrant 
expression of Lewis-type antigens appears to be a general cancer-
associated phenomenon, reported in carcinomas of the lung [10], colon [5, 
11, 12], stomach [13] and kidney [14]. sLe(a) is the epitope of CA19.9 
antigen, which is present in human serum and found elevated in various 
diseases [15-17] including cancers of the digestive tract, as pancreas [16, 
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18], bile ducts [19], stomach [20], and colon [17, 21]. The interest in the 
expression of sialyl Lewis antigens in cancer increased enormously after 
the discovery that sLe(x) and sLe(a) acted as ligands for E- and P-selectin 
cell adhesion molecules expressed on activated endothelial cells [22, 23]. 
The physiological role of E- and P-selectins is to mediate leukocyte 
extravasation at the sites of tissue damage or injury [24]. However, these 
molecules may also regulate the metastatic cascade by forming emboli of 
cancer cells and platelets and favouring their arrest on endothelia [25-28]. 
The relationship between expression of sialylated Lewis antigens and 
hematogenous metastasis is suggested by many clinical and experimental 
studies [29] (Figure 1.2). In colon cancer patients, increased expression of 
sLe(x) and sLe(a) antigens correlated with metastasis and poor survival 
[30, 31]. sLe(x) correlated with malignancy also in renal cell carcinoma [32] 
and breast cancer [33] although in the latter the survival did not appear to 
be related with sLe(x) expression [34]. 
sLe(x) antigen structures are usually present at the terminal non-reducing 
end of polylactosaminic chains of glycoproteins and glycolipids [4, 5], 
preferentially mounted on the β1,6-branching in the case of N-linked 
glycoproteins. The β1,6-branching of N-linked chains consists in the 
addition of an antenna whose first GlcNAc is β1,6-linked to a core mannose 
residue. This antenna is preferentially elongated by polylactosaminic 
sequences and is frequently terminated by antigens of the Lewis type. 
Although the association of β1,6-branching with metastasis has long been 
known [35], the conclusive evidence about the causative role played by 
these structure in metastasis formation came from studies in mice in which 
the enzyme responsible for this modification, β1,6 N-
acetylglucosaminyltransferase V (GnT5 product of the Mgat5 gene), was 
knocked down (Mgat5-/-). Mice expressing the polyomavirus middle T 
antigen (PyMT) from a transgene in mammary epithelium, spontaneously 
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develop mammary tumors. When these mice were crossed with Mgat5-/- 
mice, the tumors grew slower than in the PyMT-transgenic littermate 
expressing Mgat5 and metastasis formation was almost completely 
inhibited [36]. The relationship between β1,6-branching and increased 
growth and metastasis is probably due to more than one mechanism [37].  
In some cell lines, the major glycoproteins carrying sialyl Lewis antigens 
have been identified as the hyaluronate receptor CD44 [26, 38, 39], mucin 
1 (MUC1) [40-42] and lysosomal membrane glycoproteins 1 and 2 (LAMP-1 
and LAMP-2) [42]. 
Several studies have reported that downregulation of sialyl Lewis antigen 
expression by knockdown of key glycosyltransferases in cancer cell lines 
resulted in reduced selectin binding and reduced metastatic ability [43-46], 
while cancer cells forced to express sialyl Lewis antigens by gene transfer 
exhibited increased adhesion to selectins in vitro and increased metastatic 
ability in vivo [47]. Consistently, populations of cancer cells selected for 
their increased metastatic potential often displayed increased expression of 
sialyl Lewis antigens [48, 49]. The role of selectins in the metastatic 
process was confirmed by the findings that the formation of experimental 
pulmonary metastases could be inhibited by the use of peptides mimicking 
sLe(a) and were inhibited in E-selectin- knock-out mice [50]. 
Apart from the role as selectin ligands, sialyl Lewis antigens can play a role 
in cancer progression in at least two other key steps of invasion: 
angiogenesis and immune recognition of cancer cells. The role of sLe(x) in 
angiogenesis is supported by the finding that when epidermoid cancer cells 
were co-cultured with endothelial cells, the former produced nests of 
growing cells surrounded by tube-like networks consisting of endothelial 
cells. These phenomena could be reproduced in vivo and could be inhibited 
by antibodies against sLe(x) [51]. The ability of sLe(x)-expressing cancer 
cells to promote angiogenesis was confirmed by the fact that inhibition of 
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sLe(x) biosynthesis in hepatocarcinoma HepG2 cells resulted an 
impairment of their ability to induce angiogenesis [52]. 
 
 
Figure 1.2. Representation of the multi-step process of hematogenous 
metastasis of cancer [53]. The process starts with the intravasation of 
cancer cells into the bloodstream in the primary tumor lesion. Cancer cells 
then travel through the bloodstream, where they interact with various blood 
cells such as leukocytes and platelets, finally adhering to endothelial cells 
somewhere in the peripheral vessel walls. The interaction of E-selectin on 
endothelial cells and sialyl Lewis a/x determinant on cancer cells is involved 
in cell adhesion. 
 
The role of sLe(x) in the recognition of cancer cells by natural killer (NK) 
cells stemmed from the unexpected observation that melanoma cells 
expressing high sLe(x) levels were less metastatic than cells expressing 
moderate levels of the antigen [54, 55]. This striking behavior was 
explained by the finding that high sLe(x)-expressing cells were a better 
target of NK cells than cells expressing moderate levels of the antigen [55]. 
Altogether, these findings indicate that sialyl Lewis antigens are important 
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in mediating key steps of the metastatic process, in particular the adhesion 
of emboli of cancer cells to endothelia and neoangiogenesis. Nevertheless, 
very high expression levels of sLe(x) can trigger a strong NK-mediated 
tumor rejection [56].  
The terminal steps of the biosynthesis of sialyl Lewis antigens proceeds 
from the α1,3/4 fucosylation of α2,3-sialylated type 1 (sLe(a)) or type 2 
(sLe(x)) chains. On this basis the role of α1,3/4 fucosyltransferases and 
α2,3 sialyltransferases in the cancer-related over-expression of sialylated 
Lewis antigens has been the focus of intense investigation. It should be 
noted that the forced expression or down-regulation of α2,3 
sialyltransferases [47, 57] or of α1,3 fucosyltransferases [43, 45] or of core 
2 β1,6 N-acetylglucosaminyltransferase (C2GnT) [58] could modulate the 
expression of sialyl Lewis antigens in experimental systems. However, this 
does not necessarily imply the regulatory role of each mentioned 
glycosyltransferase in vivo. There are at least four enzymes which can 
mediate the addition of fucose in α1,3 linkage to an α2,3-sialylated type 2 
chain: fucosyltransferases III, V, VI and VII (FUT3, FUT5-7), while only one 
(FUT3) can add fucose efficiently in α1,4-linkage to an α2,3-sialylated type 
1 chain. The expression of sLe(x) appears to be regulated mainly by FUT6 
in breast tumors [59], while in lung tumors it is regulated by a coordinate 
up-regulation of FUT3 and FUT6 [60]. In gastrointestinal tumors, such as 
pancreatic cancer, the over-expression of sLe(x) antigen seems to correlate 
with an augmented expression of α2,3-sialyltransferases ST3Gal III and 
ST3Gal IV [61]. In colon cancer, the molecular basis of the over-expression 
of sialyl Lewis antigens are particularly complex. An investigation on the 
level of activity of the fucosyltransferases synthesizing sLe(a) or sLe(x) 
concluded that an altered activity of fucosyltransferases could not explain 
the increased expression of sLe(a)/sLe(x) antigens in colon cancer tumors 
[62]. Consistently, other investigations reported that the mRNA level of 
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different fucosyltransferases and sialyltransferases involved in the 
biosynthesis of sialylated Lewis antigens could not explain their increased 
expression in colon cancer tissues [63, 64].  
However, the biosynthesis of sialyl Lewis antigens is a complex process 
involving the coordinate expression of several glycosyltransferases, which 
might be different depending on the nature of the glycoconjugate (N- or O-
linked chains of glycoproteins or glycolipids) carrying the antigen. In fact, 
the expression of both sLe(x) and sLe(a) antigens expressed by glycolipids 
in colon cancer tissues has been related to the activation of a β1,3GlcNAc 
transferase which synthesizes a sugar chain which is a precursor for both 
type 1 and 2 Lewis structures [65]. Interestingly, this enzyme is activated by 
Helicobacter pylori infection, leading in stomach cells to increased 
expression of sLe(x), which is a ligand for H. pylori sialic acid-binding 
adhesin SabA [66].  
On the other hand, the relative abundance of type 1 and type 2 chains is an 
important factor in determining the relative level of expression of 
sLe(x)/sLe(a) antigens. An up regulation of lactosaminic chains [67] and of 
their biosynthetic enzymes β1,4-galactosyltransferase I [68] and -IV [69] 
and a down-regulation of the B3GALT5 which synthesizes type 1 chains in 
epithelia [1, 70] (Figure 1.1), has been reported in colon cancer [71-73] 
indicating a switch towards the synthesis of type 2 chains in the 
transformation of colonic tissues. The key role of B3GALT5 in the 
regulation of the balance between type-1 and -2 chains was also indicated 
by the finding that suppression by anti-sense DNA of B3GALT5 resulted in 
down-regulation of sLe(a) and up-regulation of sLe(x) and lactosaminic 
chains in the pancreatic cancer cell line BxPC3 [74].  
The down-regulation of the biosynthesis of type 1 chains in colon cancer 
tissues leaves unanswered the question on the origin and the nature of the 
circulating CA19.9 present in the blood of several patients affected by 
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various cancers of digestive organs. Recent data from our lab 
demonstrated that no antigen is detectable in colon cancer homogenates, 
by dot-blot or enzyme immunoassay. In cancer cell lines synthesizing 
CA19.9, the amount of antigen secreted is proportional to that expressed 
on the cell surface, and depends on appreciable levels of B3GALT5, which 
appear much higher than those measured in colon cancer specimens. In 
cancer samples, B3GALT activity was closely related with B3GALT5 
transcript down-regulation. Since colon cancers appear unable to 
synthesize relevant amount of CA19.9, it was suggested that the metabolic 
origin of the circulating antigen should be searched in other tissues actually 
able to synthesize and secrete relevant amounts of CA19.9 [17].  
1.3 B3GALT5 transcription is driven by multiple promoters  
The mRNA corresponding to the B3GALT5 coding sequence was found 
expressed in epithelia of various gastrointestinal tissues and some related 
cell lines [1], and strongly down-regulated in colon cancer [72]. A single 
transcription starting site was recognized, and then a 5’ flanking region was 
found able to act as a promoter [71]. HNF1 and Cdx transcription factors 
were proposed to control B3GALT5 expression [71] according to a model 
reported for the typical intestinal enzyme sucrase-isomaltase. Very 
interestingly, it was found soon later that the entire exon 1 of this B3GALT5 
transcript, as well as the putative HNF1/Cdx binding motive in the 5’flanking 
promoter region, belonged to a retroviral long terminal repeat (LTR) 
sequence [75] also present in genomes of Old World monkeys, but not in 
New World monkeys or mice. The sequence of the B3GALT5 LTR proximal 
promoter region was found highly similar in all primate species tested. 
Indeed, non-transcribed LTR nucleotides 1-174 were 97.1% identical 
between the human and baboon sequence. The sequence identity of the 
full-length LTR was 92.2%, comparable to the expected identity between 
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human and Old World monkey non-coding DNA. These findings dated the 
insertion of the transposon to 25-30 million years ago, and suggested the 
existence of another ancestral promoter [76].  
Later on, Mare and Trinchera characterized multiple B3GALT5 transcription 
initiation sites and cognate 5’UTRs, as well as distinct 5’ flanking regions 
active as promoters [77] (Figure 1.3). Among them, the type A promoter, 
sensitive to CCAAT-binding factor (also named NF-Y), was proposed as 
the native promoter. This ancestral promoter conserved in mouse, where it 
acts as a unique B3GALT5 promoter, has substantial gastrointestinal 
specificity in this specie, as previously suggested [76]. This type A promoter 
provides low B3GALT5 expression in both humans and mice. In humans, it 
is located about 42 Kbp upstream of the LTR sequence in the context of 
CpG islands, appears active in many epithelia, such as mammary gland, 
thymus and trachea, but weak and down-regulated in cancer through 
epigenetic mechanisms [78]. A common role of B3GALT5 in some general 
mammalian cell function may be proposed when it is transcribed under the 
control of this promoter. Little information is currently available concerning 
type 1 chain expression in the mouse [79, 80], where α1,4 fucosylation 
does not occur [81]. Moreover, it is not presently clear how B3GALT5 
predominates in the murine gastrointestinal tract, as it happens in the 
human counterpart, simply using the native promoter despite the absence 
of the LTR promoter in this species. 
The type B promoter, located about 27 Kbp upstream of the LTR in 
humans, appeared as a defective weak promoter having the same 
HNF1/Cdx binding sequence as the LTR promoter, but placed in the 
opposite orientation. Because of such a perfect sequence match, it was 
supposed that the type B promoter helped stabilize the LTR promoter at the 
time of its transposition. A suggestive hypothesis is that the type B 
sequence represents a remnant of a true native promoter that was relevant 
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at the time of the transposon insertion but has been overwhelmed by the 
mobile element [77].  
The type C promoter was found to be a rather strong promoter active in the 
small intestine only. It is placed about 17 Kbp upstream the LTR sequence 
and its binding sites for transcription factors remain unknown. On the other 
side, the brain-specific promoter appeared to be a very weak promoter 
whose relevance is uncertain because the expression levels of B3GALT5 in 
brain are extremely low. In fact, other β1,3-galactosyltransferases, such as 
B3GALT1 [8, 70] and B3GALT2 [7], are expected to play a major role in 
tissues and cells of neuroectodermal origin. All B3GALT5 transcripts driven 
by such promoters share a common 3’ sequence including exons 3 
(untranslated) and 4 (spanning the entire coding sequence), and differ for 
their 5’UTRs only (Figure 1.3). 
 
 
Figure 1.3. Genomic structure of the human B3GALT5 gene [77]. The 
positions of the exons in the context of human chromosome 21 are shown 
following the nucleotide (nt) numeration of the available sequence 
(GenBankTM accession number AF064860). The structure of the 5'-UTRs 
of B3GALT5 mRNA with their splice variants is presented together with the 
reported LTR-derived 5'-UTR. 
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1.4 Transposable elements 
Remarkably, almost half of eukaryotic genomes comprise transposable, or 
transposed, elements (TE). These are repeated and mobile DNA 
sequences, with the capacity to replicate, move across genomes and 
invade them.  
TEs can be separated into two major classes depending on their 
transposition mechanisms (Figure 1.3). Class I elements, called 
retrotransposons, move via a reverse-transcribed RNA intermediate and 
are represented by long terminal repeat (LTR)/endogenous retrovirus 
(ERV) elements, non-LTR retrotransposons (such as long interspersed 
nuclear elements (LINEs)) and non-autonomous elements (short 
interspersed nuclear elements (SINEs) such as Alu and the composite 
primate family of elements termed SVA [82, 83]. Class II elements replicate 
without an RNA intermediate, either by a cut-and-paste mechanism (DNA 
transposons containing transposases), by rolling-circle DNA replication 
(helitrons), or by mechanisms that remain unknown (polintons/mavericks). 
Class II elements also include non-autonomous TEs, such as truncated 
DNA transposons and miniature inverted-repeat TEs (MITEs) [84]. Each 
family can be further separated into subfamilies based on TE structure and 
evolutionary aspects (such as DNA sequence homology). 
TEs are genetic units bringing positive, neutral, or negative effects to the 
host. They serve as recombination hot spots and may acquire specific 
cellular functions, such as controlling protein translation and gene 
transcription [85]. One of the most direct influences of transposable 
elements on the host genome is their role in modulating the structure and 
expression of “resident” genes. 
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Figure 1.4. Schematic overview of the TE repartition in the human genome 
[83]. Transposable element as a whole represents about 45% of the human 
genome. The diagram represents the percentage of each TE category 
compared to all transposable elements (first %) and over the entire human 
genome (% in brackets). 
 
Many TEs have been described in the last decade that can add a variety of 
functions to their targeted genes. These include alteration of splicing 
patterns, premature transcription termination, increased recombination, 
alternative promoter use [86, 87], polyadenylation sites, enhancer and 
silencers effects [88]. It seems that a sizable fraction of eukaryotic gene-
associated regulatory elements arose in this modular fashion by insertion of 
TEs, and not only by point mutations of static neighboring sequences. 
When a TE is inserted upstream from a gene, a few short motifs can be 
conserved if they were subjected to selective pressure as promoters or 
enhancers of transcription. Even though the rest of the TE sequence might 
evolve beyond recognition due to absence of functional constraints, TEs 
are hence exapted into a novel function [89]. Retrotransposition activity 
itself is a source of raw genetic material for evolution, resulting in variability 
within and among species [90, 91]. 
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1.4.1 LTR elements as promoters 
After discovery that LTRs carry promoter and enhancer motifs, it became 
clear that integration of such elements in proximity of a host gene must 
have an influence on this gene expression [92]. Although LTRs are widely 
distributed in the human genome, their distributions along the human chro-
mosome are not only non-random but also associated with gene density 
[93]: they are enriched in the regions of transcription units. LTRs can be 
located in the sense and antisense orientation of its adjacent gene and at 
any region, including 5'UTR, intron, exon and 3'UTR. These distributions 
provide favorable conditions for LTRs regulating the expression of their 
neighboring genes in different ways [94]. LTR elements can benefit from 
genes by surviving from one generation to the next, while genes can benefit 
from LTR characteristics. For example, genes could obtain their promoter 
(sometimes bidirectional) [75, 76, 95, 96], enhancer [95], polyadenylation 
sites [97, 98], alternative splicing pattern [99] from LTRs.  
The LTR promoters active in the modern human genome are likely to have 
beneficial or neutral effects because if an LTR insertion results in a 
detrimental change in gene expression it will be selected against and will 
not become fixed in the population [100]. A significant role for ERVs in 
shaping gene regulatory networks is starting to be revealed through whole 
genome analyses that show functional transcription factor binding sites 
(TFBSs) are commonly present within LTR sequences. Binding sites for the 
transcription factors p53, CTCF, Pou5F1-Sox2 and ESR1 are enriched 
within individual LTR sequences and are also present in LTR consensus 
sequences [101, 102].  
Major LTR promoter-induced expression changes are actually the 
exception to the rule. In most cases, the LTR promoter exerts a relatively 
subtle effect on the tissue specificity of expression and is likely to only 
augment expression from the native promoter [100]. Deviations from this 
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trend are found in placenta, a tissue in which ERVs are known to be more 
transcriptionally active [103, 104] and where LTR promoters do indeed tend 
to confer tissue-specific expression. 
1.4.1.1 Alternative promoters  
Individual cases of alternative gene promoters have long been described 
and more recent genome-wide studies have estimated that up to 75% of 
human genes use alternative promoters, perhaps far more than anticipated 
[105-107]. The varying genetic structure of alternative promoters results in 
different functional effects [108, 109]. In most cases, the two or more 
alternative promoters each contribute an alternative first exon containing 
distinct transcription start sites. The translation initiation codon is within a 
common downstream exon so the same protein is formed regardless of 
promoter use [110-112]. The main functional consequence of such an 
alternative promoter is to drive different transcription patterns, for example 
in different tissues, at different developmental stages or at different levels of 
expression [113, 114]. However, if two or more alternative first exons each 
contain unique translation initiation sites, they will encode proteins with 
different N-terminal but identical C-terminal sequences [115, 116]. 
Alternative promoter use can also regulate alternative splicing products, 
resulting in the production of different protein isoforms [117, 118]. These 
changes in protein sequence may result in loss or gain of alternative 
functional domains or may change the subcellular localization due to the 
inclusion or exclusion of signal peptides. Alternative promoters can even 
drive translation of different open reading frames producing completely 
different proteins [119, 120] and can affect the translation efficiency of 
different isoforms. The mechanisms that control alternative promoter use in 
different cellular states are not very well studied but probably involve either 
availability of regulatory proteins, such as transcription factors, or 
epigenetic mechanisms such as DNA methylation [108].  
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1.4.1.2 LTR exaptation as primary promoter  
In most cases, the LTR is one of two or more alternative promoters, but 
there are examples where the LTR is the sole or primary promoter.  
The LTR12C (HERV-9) promoter of GBP5 (guanylate binding protein 5) 
confers an expression pattern in lymphocytes, endothelial cells and a 
lymphoma cell line that is similar to that of its paralog, GBP1 [121, 122]. 
There is evidence that BAAT (bile acid CoA: amino acid N-acyltransferase) 
and MSLN (mesothelin) have non-TE alternative promoters as well as their 
characterized LTR promoters [123]. For BAAT, the alternative promoter 
also appears to be liver-specific. The contribution of the MSLN native 
promoter is unknown, but the LTR promoter has been characterized and 
acts as a core promoter with additional non-LTR enhancers required for 
specific, functional expression in mesothelium [124, 125]. ADH1C (alcohol 
dehydrogenase 1C) involved in the alcohol metabolism, and HSD17B1 
(hydroxysteroid 17-beta dehydrogenase 1) involved in estrogen synthesis 
in breast cancer are other examples of LTR exapted as primary promoters 
[100].  
1.4.1.3 Placental specificity of LTRs 
In many species ERVs are highly transcribed in germ line cells, testis and 
placenta [103, 104, 126] so it is not surprising to find that LTR promoters 
are also more active in these tissues. CYP19A1 (cytochrome P450, family 
19, subfamily A), IL2RB (interleukin 2 receptor, beta), NOS3 (nitric oxide 
synthase 3) and PTN (pleiotrophin) are all examples of genes whose 
expression in the placenta is solely due to the presence of the LTR 
promoter [100]. The placental expression of genes with LTR promoters may 
be an artifact of the evolutionary mechanism of endogenization since 
retroviruses that were more active in reproductive tissues may have been 
more likely to be able to infect germ cells. Assuming this hypothesis, we 
might predict that active LTRs will preferentially contain binding sites for 
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placental or reproductive tissue-specific transcription factors. An alternative 
theory, not mutually exclusive, is that ERV LTRs are less methylated in 
germ line cells and reproductive tissue [127], although in a recent study this 
could not be concluded to be the sole mechanism of ERV LTR 
transcriptional regulation in the placenta [128]. Further studies are required 
to understand fully the regulatory mechanisms by which LTR promoters are 
more active in the placenta (and potentially other reproductive tissues) than 
other somatic cells. 
A further point to consider is whether the LTR-driven gene expression in 
the placenta has any functional consequence, regardless of the mechanism 
by which expression is achieved. Expressed ERV genes are known to have 
been exapted in the placenta, for example the HERV-W Env gene Syncytin 
has acquired a functional role in placental syncytiotrophoblast formation 
[129, 130]. In several cases (PTN, CYP19A1, and PAPPA2) orthologs in 
other mammals are also expressed in the placenta, but not due to retroviral 
insertion [131]. In these cases the gene function, rather than the regulatory 
mechanism by which it is expressed, has been conserved, suggesting that  
their placental expression is actually a result of convergent evolution rather 
than a novel function of the LTR insertion. For EDNRB (endothelin receptor 
type B), ENTPD1 (ectonucleoside triphosphate diphosphohydrolase) and 
MID1 (midline 1) the LTR promoter augments placental expression rather 
than providing novel specificity, and these genes are known to have 
functional effects in the placenta. Similarly, the LTR promoter of INSL4 
(insulin-like 4) has been exapted as the primary promoter and confers the 
expression that enables INSL4 to have a role in placental morphogenesis 
[131, 132]. However, there are a number of cases (IL2RB, NOS3 and 
HSD17B1) for which the functional effects of placental expression remain 
unknown. 
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1.4.2 Evolutionary models for LTR insertion 
There are some possible evolutionary scenarios in which an LTR insertion 
upstream of a cellular gene results in the LTR developing into a promoter 
(Figure 1.5). Models (a) and (b) show LTR insertions that evolve as 
alternative promoters under two basic evolutionary scenarios. Upon 
integration LTRs will naturally contain transcriptional regulatory motifs, such 
as TFBSs, necessary for the retroviral life cycle. The first case (a) 
describes a model in which TFBSs present in the original LTR insertion that 
maintains functional roles are conserved more than non-functional TFBSs. 
Dunn et al. have proposed this model for the case of B3GALT5 on the 
basis of sequence comparison between the specific LTR copy, the LTR 
consensus sequence and insertions in other primates [76]. This model is 
also supported by genome-wide studies analyzing the distribution of TFBSs 
within LTRs that show the presence of regulatory motifs within consensus 
LTR sequences [101, 102]. In the second scenario (b), TFBSs have been 
acquired through novel mutations in the LTR and consequently are only 
present in individual LTR sequences, not in the consensus sequence for 
that family. Scenaries (c) and (d) depict evolutionary outcomes that relate 
to other examples described above. In model (c), transcription from the 
LTR promoter gives the same expression pattern as the main promoter 
leading to two possible outcomes; (i) the LTR is exapted as the primary 
promoter; (ii) the LTR promoter activity is lower than the native promoter so 
its effect is minor. Sometimes, important functional binding sites may lie 
upstream of the LTR in which case the LTR contains core promoter 
elements and tissue specific or additional activating factors are contributed 
by the host genome (Model d). Although not specifically depicted, this 
scenario could again result in the LTR becoming the primary promoter of 
the gene, or one of two alternative promoters. 
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Figure 1.5 Evolutionary models of LTR promoter generation and 
maintenance modified from [100] (a) Insertion of an LTR (grey arrow) with 
pre-existing tissue-specific or general TFBSs (green and blue ovals) 
upstream of a native promoter (black bent arrow) results in novel tissue-
specific expression from the LTR promoter (red bent arrow). Over 
evolutionary time (moving from left to right), only functional TFBSs are 
maintained. (b) A similar scenario to (a), except functional TFBSs are not 
present in the original LTR insertion but evolve over time. (c) An LTR 
insertion contributes an alternative promoter with the same specificity as 
the native promoter, resulting in (i) loss of the native promoter or (ii) a minor 
effect. (d) An LTR insertion contributes core promoter activity and upstream 
TFBSs contribute tissue-specific effects. 
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1.5 Genes expression regulated through DNA methylation 
Until recently, the majority of DNA methylation studies focused on the 
analysis of CpG islands associated to promoter regions. Experimental 
evidence demonstrated that gene expression can be regulated by DNA 
methylation levels of CpG islands in the proximity of transcription start sites 
[133]. Based on these data, the majority of cancer-related DNA methylation 
studies focused on the role of CpG islands hypermethylation as a 
mechanism of tumor suppressor gene silencing [134, 135]. For explaining 
this phenomenon, some models are been proposed. One of the most 
accepted models is that gene silencing is mediated by proteins containing a 
methyl-CpG binding domain (MBD). MBD binding to methylated CpG 
islands is followed by recruitment of histone deacetylases, chromatin 
compaction and gene silencing [136, 137] (Figure 1.6a). Another possible 
model involves DNA methylation dependent transcription factor binding to 
their recognition sites; if the DNA is methylated, the transcription factor 
cannot bind to the promoter region and therefore, the gene is inactive [138, 
139]. 
However, already in the 1980s, pioneer studies in cancer cells reported that 
neoplastic transformation was also associated with global and gene specific 
loss of DNA methylation [140, 141]. Hypomethylation of transcription 
regulatory regions in cancer seems to be much less frequent than 
hypermethylation of CpG islands overlapping promoters [141-143]. 
Nonetheless, some of the cancer-associated loss of DNA methylation 
encompasses gene regions, including transcription control sequences [144-
146]. 
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With the upcoming possibilities to study DNA methylation in a genome-wide 
context, this epigenetic mark can now be studied in an unbiased manner. 
As a result, recent studies have shown that DNA methylation does not 
occur exclusively at CpG islands. The term CpG island shores, referring to 
regions of lower CpG density that lie in close proximity (~2 kb) of CpG 
islands, has recently been described. The methylation of these CpG island 
shores is closely associated with transcriptional inactivation (Figure 1.6b). 
Most of the tissue-specific DNA methylation seems to occur not at CpG 
islands but at CpG island shores [147, 148]. Differentially methylated CpG 
island shores are sufficient to distinguish between specific tissues and are 
conserved between human and mouse.  
 
 
 
Figure 1.6 Effects of DNA methylation in different regions of the genome 
modified from [149].(a) CpG islands at promoters of genes are normally 
unmethylated, allowing transcription. Aberrant hypermethylation leads to 
transcriptional inactivation. (b) The same pattern is observed when studying 
island shores, which are located up to 2 kb upstream of the CpG island. (c) 
However, when methylation occurs at the gene body, it facilitates 
transcription, preventing spurious transcription initiations. In disease, the 
gene body tends to demethylate, allowing transcription to be initiated at 
several incorrect sites. 
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Although DNA methylation mainly occurs in the CpG dinucleotide context in 
mammals, non-CG methylation has recently been described in humans at 
CHG and CHH sites (where H is A, C or T) [149]. CHG and CHH 
methylation has been found in stem cells and seems to be enriched in gene 
bodies directly correlated with gene expression and to be depleted in 
protein binding sites and enhancers [150]. The levels of non-CpG 
methylation decrease during differentiation and are restored in induced 
pluripotent stem cells, suggesting a key role in origin and maintenance of 
pluripotent state [150, 151]. Mechanisms of non-CpG methylation remain 
unclear [151]. 
In addition to 5-methylcytosines, 5-hydroxymethyl-2′-deoxycytidine has also 
been observed. So far, 5-hydroxymethyl-2′-deoxycytidine has been 
reported in Purkinje cells constituting less than 1% of total nucleotides, but 
it seems not to be present in cancer cell lines [149]. These new DNA 
modifications need to be further studied to determine their implications for 
normal and diseased epigenetic regulation. 
Additionally, not only promoters but also intragenic and intergenic regions 
are widely modulated during physiological processes and disease. In 
particular, it is becoming clear that DNA methylation in the gene body 
widely change during cell differentiation and carcinogenesis. It seems to be 
actively involved in multiple gene regulation processes, such as transcript 
elongation, expression of intragenic coding and non-coding transcripts, 
alternative splicing and enhancer activation. 
1.5.1 Intragenic DNA methylation and gene expression 
The negative correlation between gene expression and CpG islands 
methylation at the transcription start sites is well established. However, this 
association cannot be extrapolated to other genomic contexts such as 
CpGs located in the gene body. Gene body methylation is common in 
ubiquitously expressed genes and is positively correlated with gene 
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expression [152]. It has been proposed that it might be related to elongation 
efficiency and prevention of spurious initiations of transcription (Figure 
1.6c). In general, DNA methylation is thought to block transcription initiation 
but not elongation. In fact, intragenic nucleosomes with trimethylation of 
H3K36, which is associated with transcript elongation, seem to recruit DNA 
methyltransferases, thus facilitating the methylation of intragenic DNA 
[153]. Therefore, even if the gene body is highly methylated, which is a 
frequent finding in normal undifferentiated cells, the gene may be 
transcribed. This can lead to an apparent contradiction, as DNA 
methylation in the promoter can be negatively associated with gene 
expression whereas the methylation status in the gene body of the same 
gene can show a positive correlation. A positive correlation between 
intragenic DNA methylation and gene expression has been recently 
observed in multiple genome-wide epigenomic studies, both in the context 
of cell development and differentiation as well as in cancer cells [154, 155]. 
An interesting study observed a context-dependent correlation of CpG 
gene-body methylation, related to whether the CpGs were located in or 
outside intragenic CpG islands. For CpGs outside intragenic CpG islands, 
the methylation status correlated positively with gene expression, while for 
CpGs located within CpG islands, the methylation status can either be 
positively or negatively correlated with gene expression levels. Only for 
approximately 15% of the intragenic CpG islands presenting a negative 
correlation, an association with specific gene regulatory processes, e.g., 
alternative promoter usage or intragenic enhancer activity, was found [156]. 
DNA methylation at intragenic CpG islands seems to regulate alternative 
promoter usage and to interfere with expression of the main transcripts 
[157]. It seems that DNA demethylation at alternative promoters results in 
an accessible chromatin status and binding of transcription factors as well 
as transcription initiation factors. 
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Figure 1.7 Association between intragenic DNA methylation and gene 
expression [157]. Correlation between DNA methylation and expression 
across the promoter and gene body of the LASS6 gene. Vertical bars in the 
                                                                         
region (gray shadow) show a clear negative correlation whereas most of 
the CpGs in the gene body (pink shadow) show a positive (or not significant 
(ns)) correlation between DNA methylation and gene expression levels. 
The data for this figure are derived from DNA methylation and gene 
expression arrays performed in 125 patients with chronic lymphocytic 
leukemia [158] 
 
Another role of gene-body DNA methylation is the regulation of intragenic 
non-coding RNAs (ncRNAs) present in the intronic region of numerous 
genes. They can be co-expressed with the host gene or can have their own 
promoter. Expression of many miRNAs [159, 160] and lncRNAs [161] has 
been described to be regulated by DNA methylation in a similar way as for 
protein-coding genes. Hence, alteration of DNA methylation patterns can 
be responsible for the deregulation of miRNAs or lncRNAs expression and 
consequently can alter the expression of their target genes. In addition to 
short and long ncRNAs, the expression of transposable elements has also 
been shown to be regulated by DNA methylation. It is widely accepted that 
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DNA methylation is crucial in preventing the activation of LINEs, SINEs, 
retroviruses and other transposable elements, thereby ensuring genomic 
integrity and stability [141, 142]. An additional function of intragenic DNA 
methylation is related to RNA processing mechanisms such as alternative 
splicing and alternative polyadenylation [162]. It is commonly accepted that 
alternative splicing is regulated by splicing enhancers, silencers and 
specific binding of splicing factors [163]. Furthermore, several studies have 
identified a link between epigenetics and alternative splicing [164, 165]. 
1.5.2 DNA methylation at enhancers 
Different genome-wide and single gene studies demonstrate that a large 
number of enhancers show a reverse correlation between DNA methylation 
and gene expression levels or enhancer activity [166, 167]. Aran et al. have 
found that a subset of the predicted enhancers was hypo- or 
hypermethylated in the cancer cells compared to the normal cells, thus 
enhancer methylation is remarkably altered in cancer [167]. Moreover, they 
showed that enhancer methylation is more closely related to changes in 
gene expression than promoter methylation. This indicates that in some 
cases, surprisingly, the methylation status of distal regulatory regions might 
be more predictive for expression levels than promoter methylation itself 
[167]. Similar results were obtained in a large study, in which the strongest 
correlation between gene expression and DNA methylation was found in 
intragenic CpGs rather than for those located at 5′ regions. Furthermore, 
the negative correlation between intragenic DNA methylation and gene 
expression was frequently related to enhancer regions [158]. A rather new 
phenomenon that sheds light on enhancer activity is expression of non-
coding RNAs from enhancer sequences (eRNAs) [168]. Expression of 
these eRNAs is correlated with transcription levels of nearby located genes. 
Interestingly, it was recently shown by Melo et al. that induction of eRNA 
expression by p53 may occur at loci with a pre-programmed chromosome 
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conformation state. At these loci, p53 responsive enhancer elements are 
already located in close proximity to their target genes, while p53 binding 
and consequent eRNA expression are the final, essential steps that 
facilitate expression of p53 target genes [169]. 
Many factors are involved in transcription regulation at the enhancer level, 
e.g., protein binding, formation and stabilization of long range promoter-
enhancer interactions and expression of eRNAs. Hence, the effect of DNA 
methylation changes on transcription potential may vary in a similar 
context-dependent manner. 
 39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. RATIONALE 
Rationale 
40 
 
HNF1 is important for liver specific expression of a variety of genes 
including albumin, α1-antitrypsin, and β-fibrinogen [170, 171]. Although 
originally described as liver-specific [172], HNF1 has subsequently been 
shown to be expressed not only in liver but also in kidney, intestine, 
stomach and pancreas [173-175]. Studies on HNF1- knocked out mice 
have revealed that this transcription factor is crucial for the transcriptional 
activation of genes that play key roles in liver (in phenylalanine catabolism), 
pancreas (in β-cell glucose-sensing), and in kidney (in the renal proximal 
tubular reabsorption of glucose) [176]. Additionally, mutations in the human 
HNF1 gene, in the heterozygous state, have been found to be responsible 
for particular forms of diabetes mellitus termed maturity-onset diabetes 
mellitus of the young (MODY-3 and MODY-5) [177].  
Sucrase-isomaltase is another example of a non-hepatic gene regulated by 
HNF1 [178] that is expressed in a strict tissue, position and cell lineage-
dependent pattern. Absorptive enterocytes located on villi in the small 
intestine are the only cells in the body that express mRNA [179] or protein 
[180]. Not only HNF1, but also Cdx1 and Cdx2 [181] and GATA-4 [182] 
have been described as primary transcription factors that can cooperate in 
the regulation of this gene. Sucrase-isomaltase expression pattern has 
been extensively investigated [178-182] and extrapolated to explain a 
general model of regulation of intestinal genes. However, re-evaluation of 
the tissue distribution of the various B3GALT5 mRNAs [77] indicated that 
the LTR transcript was very highly expressed only in normal colon mucosa, 
while in the other organs of the gastrointestinal tract, including the small 
intestine, it is present in lower amounts. Such expression pattern was thus 
opposite to that reported for sucrase-isomaltase, which instead is active in 
the small intestine [178-180].  
Moreover, according to such expression model depending on HNF1 and 
Cdx, we should expect: 1) Not to find HNF1 expressed on colon cancers 
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biopsies which express low levels of B3GALT5 LTR transcript. However, in 
previous experiments we determined HNF1 in such samples and we found 
appreciable levels of HNF1. 2) If the LTR expression depends on Cdx, then 
this factor should be expressed on cell lines expressing high levels of the 
LTR transcript. Nevertheless, it was reported that COLO-205 cells, 
expressing extremely high levels of B3GALT5 mRNA, including the LTR 
transcript [1, 74], were devoid of any Cdx expression [183]. These findings 
appeared not compatible with the proposed model of B3GALT5 
transcription and prompted us to re-evaluate it in details.  
Strategy 
To determine the role of the putative transcription factors HNF1α/β and 
Cdx1/2 in B3GALT5 transcription, we compared the expression levels of 
the B3GALT5 LTR transcript, quantitated by competitive RT-PCR, with 
those of transcription factors, determined by western blot analysis, in colon 
cancer biopsies, in various cell lines, and in cell models serving as controls. 
They included cells transfected with plasmids coding HNF1α/β cDNAs or 
shRNAs in order to corroborate if the overexpression or silencing of those 
factors can modulate LTR transcript expression. Although the LTR 
promoter and the proximal sequences do not have CpG islands, we treated 
cells expressing the LTR transcript with the demethylating agent 5AZA to 
understand the effect of this epigenetic feature on the activation of 
B3GALT5 LTR promoter. Finally, we evaluated the behavior of the LTR 
promoter in vitro, through electrophoresis mobility shift and reporter 
luciferase assays. 
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This study is aimed to comprehend the regulation of B3GALT5 LTR 
promoter in order to:   
I. Elucidate the role of candidate transcription factors and the presence of 
potential epigenetic marks, to explain tissue specific expression and 
regulation, mainly in the process of colon tumorigenesis.  
II. Understand the evolutionary stabilization of the transposon occurred in 
humans and some primates.  
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4.1 Materials 
4.1.1 Cell lines 
Human breast cancer cell lines MCF-7 and MDA-MB-231, human gastric 
cell line MKN-45 and KATOIII, human bile duct carcinoma cell line HuCC-
T1, and human colon cancer cell lines HT-29, HCT-15, COLO-205 and SW-
1116 were cultured as reported [74, 77, 78, 184]. Human breast cancer cell 
line MDA-MB-361, a gift of Dr. Cristina Razzari (University of Milan, Italy), 
human embryonic kidney HEK-293T/17 (ATCC CRL-11268), a gift of Dr. 
Anna Menini (SISSA, Trieste, Italy) and human hepatoma cell lines Huh-7 
and Hep-3B, a gift of GIM microscopy group (University of Milan, Italy), 
were cultured in DMEM containing 10% fetal bovine serum, 100 U/ml 
penicillin, 1 mg/ml streptomycin, and 2 mM l-glutamine.  
4.1.2 Human biopsies 
Human colon biopsies were as reported [72, 184]. This study was approved 
by the Senior Committee Board regulating non interventional studies, 
comparable to an Institutional Pre-review Board. All patients underwent 
surgery for colorectal cancer at Bologna University Hospital. After careful 
examination by the Pathologist, a sample of normal and cancer tissue was 
dissected for biochemical studies. Each specimen was immediately snap 
frozen in liquid nitrogen and conserved at -80 °C.  
4.1.3 Plasmid DNAs   
The coding sequences of HNF1α, HNF1β, Cdx1 and Cdx2 were obtained 
by PCR using the below mentioned primer pairs, harboring HindIII and XbaI 
restriction sites, starting from RNA extracted from COLO-205 (HNF1α), 
MKN-45 cells (HNF1β), and from commercially available (Stratagene 
#540009, Agilent Technologies Italia) human normal mucosa RNA (Cdx1 
and Cdx2), using the reported procedure [184]. Amplified fragments were 
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restriction digested, cloned into the corresponding sites of the pcDNA3 
vector, and sequenced. Since we obtained from our source the variants 
P130R [185] and S291P [186] of Cdx1 and Cdx2, respectively, we mutated 
the obtained plasmids with the QuikChange Lightning mutagenesis kit 
(Agilent Technologies, Italia) to obtain the wild-type sequences, according 
to the manufacture’s protocol. 
Primers sequences used for cloning were:  
HNF1α Forward GCAAGCTTGCCATGGTTTCTAAACTGAGCC 
HNF1α Reverse GCTCTAGATGGTTACTGGGAGGAAGAGGCC 
HNF1β Forward GCAAGCTTGAAAATGGTGTCCAAGCTCACG 
HNF1β Reverse GCTCTAGAGGCATCACCAGGCTTGTAGAGG 
Cdx1 Forward CTAAGCTTACCATGTATGTGGGCTATGTGC 
Cdx1 Reverse CTTCTAGAGCTATGGCAGAAACTCCTCTTT 
Cdx2 Forward CTAAGCTTACCATGTACGTGAGCTACCTCC 
Cdx2 Reverse CTTCTAGATCACTGGGTGACGGTGGGGTTT 
 
Primers sequences used for mutagenesis of Cdx1 and Cdx2 were: 
Cdx1 Forward CGGAGCGCAGAGGCCGACGCCCTACGAG    
Cdx1 Reverse CTCGTAGGGCGTCGGCCTCTGCGCTCCG 
Cdx2 Forward CTGCAAGCCTCAGTGTCTGGCTCTGTCCCTGG 
Cdx2 Reverse CCAGGGACAGAGCCAGACACTGAGGCTTGCAG 
 
For gene silencing, we used Human MISSION® shRNA Plasmid DNA 
(Sigma Aldrich Italia), based on pLKO vector, clone 
TRCN0000017509NM_000458.1-800s1c1TRC 1 (targeting HNF1β), clone 
TRCN0000017194NM_000545.3-1039s1c1TRC 1 (targeting HNF1α), or 
pLKO vector alone.  
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Figure 4.1 Vector Map of pLKO.1-puro (Human Mission shRNA Plasmid 
DNA) 
4.2 Cell treatments 
4.2.1 Cell treatments with drugs 
Treatments of cells with drugs affecting DNA methylation and histone 
deacethylation were performed as reported (11). Cells were plated in 6-well 
plates, incubated 24h with regular medium that was replaced was replaced 
with medium containing different amount of 5AZA (Sigma, dissolved in 
DMSO as 10 mM stock solution) and/or TSA (Sigma, dissolved in ethanol 
as 1 mg/ml stock solution). Media were replaced every 24 h with media 
containing freshly diluted drugs. At the end of treatment cells were 
harvested by trypsinization and processed for extraction of total RNA or 
nuclear protein. 
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4.2.2 Permanent transfections 
For permanent transfection, 3x106 MDA-MB-231 cells were seeded in 100 
mm plates 24 h in advance, and 20 µg of ScaI linearized pcDNA3-HNF1α, 
pcDNA3-HNF1β, or pcDNA3 alone were mixed with 1 µg of XhoI linearized 
pLKO-puro empty vector (Sigma Aldrich Italia) bearing the puromycin 
resistance gene. Transfection solutions were prepared by diluting the 
linearized DNA with 2 ml of serum-free medium and then adding 2 ml of 
serum-free medium containing 60 μl Lipofectamine 2000 (Life Technologies 
Italia). Liposomes were allowed to form for 20 min at room temperature. 
Cells were washed twice with serum-free medium, fed with transfection 
solution, and incubated under regular growth conditions for 3-4 h. At the 
end, 8 ml of standard complete medium was added and the incubation 
continued. Two days after transfection the cells were trypsinized and 
divided into multiple plates. Selection started after an additional 24 h in the 
presence of 1 µg/ml puromycin. Resistant colonies were picked up, grown, 
and harvested to extract nuclear protein and total RNA from the same cell 
suspensions.  
4.2.3 Transient transfections  
For transient transfection, 4x106 HEK-293T cells were seeded in 60 mm 
plates 24 h in advance, and 5 µg of pcDNA3-Cdx1 or pcDNA3-Cdx2 were 
transfected in 1.5 ml of transfection solutions prepared as above for 
permanent transfection. The day after they were trypsinized and placed in 
100 mm plates in the presence of 2 mg/ml G418. After additional 5 days 
(changing media twice), resistant cells were harvested and used for nuclear 
protein extraction. 
4.2.4 Gene silencing  
For gene silencing, plasmids were linearized with BstEII (to destroy 
puromycin resistance gene) and mixed with 1/20 of the same plasmid 
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linearized with ScaI. Transfection of MKN-45 or MDA-MB-361 cells and 
puromycin selection were carried out as above described for MDA-MB-231 
cells. Individual or pooled colonies obtained upon selection were allow to 
grow 3 weeks, and the obtained cell pellets (about 0.5-1.0x106 cells) were 
washed with sterile PBS and divided in three fractions, one (0.1-0.2x106 
cells) lysed for RNA extraction, one (0.4-0.6x106 cells) mixed with protease 
inhibitor cocktail HALT (Thermo Scientific) for direct western blot analysis, 
and the remaining plated again for further growing. 
4.3 Measurements 
4.3.1 Protein extraction and Western blot 
Freshly collected cell pellets were processed to obtain nuclear extracts 
using a commercially available kit (NE-PER, Thermo scientific) as reported 
[78]. Frozen biopsies from colon were dounce homogenized and submitted 
to nuclear extraction as for cell pellets. Aliquots of nuclear extracts (5-10 µg 
of protein) were separated by 10% SDS-PAGE, transferred to a 
nitrocellulose membrane (Trans-Blot SD Semi Dry Transfer Cell, Bio-Rad 
Laboratories S.r.l, Italy) and blotted with rabbit polyclonal anti HNF1α/β (sc-
8986, 1:200, Santa Cruz Biotechnology Italia), rabbit polyclonal anti H3 
(D2B12 #4620, 1:500, Cell Signaling Technology, Italian distributor), rabbit 
polyclonal anti Cdx1 (PAB4713, 1:200, Abnova, Italian distributor), or 
mouse monoclonal anti Cdx2 antibody (M01, 1:200, Abnova) as the 
published protocol [187].  
4.3.2 RNA extraction and Competitive RT-PCR 
Quantification of transcripts was performed by competitive RT-PCR, since it 
was find very effective for distinguishing different 5’UTRs without 
underestimating splice variants [77]. Total RNA, prepared and DNase-
treated using a commercially available kit (SV total RNA isolation system, 
or ReliaPrep cell RNA miniprep, both from Promega Italia) was quantitated 
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by fluorometry with Qubit (Life Technologies Italia), and reverse transcribed 
as reported [78]. cDNAs were amplified in a volume of 25 µl in the presence 
of the indicated amounts of competitors, for 35 cycles (B3GALT5 LTR, 
HNF1α and HNF1β) or 5 pg competitor for 25 cycles (β-actin). Amplification 
program included a single treatment at 94°C for 3 min followed by cycles 
consisting of 1 min at 94 °C (melting) and 3.5 min at 72 °C (annealing plus 
extension) and a final extension step at 72 °C for 8 min (B3GALT5 and β-
actin), or 1 min at 94 °C (melting), 1 min at 66 °C (annealing) and 2.5 min at 
72 °C (extension) and a final extension step at 72 °C for 8 min (HNF1α and 
HNF1β). B3GALT5 LTR and β-actin competitors and primers were exactly 
those already reported [72, 77]. HNF1β competitor was prepared 
subcloning the coding sequence in pCDM8 vector, digesting with restriction 
enzymes BspHI and MscI, and re-ligating. HNF1α competitor was prepared 
digesting pcDNA3-HNF1α with restriction enzymes XhoI and Bsp1407I, 
blunting with Klenow, and re-ligating. 
Primers sequences used were: 
HNF1α sense 5'-GCCATGGTTTCTAAACTGAGCCAG-3’  
HNF1α antisense 5'-GTCCATAGCGCACACCGTGGAC-3’  
HNF1β sense  5’-CAGAGCCATGGGCCTGGGCAGTC-3’ 
HNF1β antisense 5’-CTGCTGGGCCATGTGGCTGCCTG-3 
 
Parallel PCR amplifications were performed on known amounts of standard 
cDNAs premixed with the competitors. Standard cDNAs were the original 
cloned sequences quantitated and diluted as for the competitors. Aliquots 
of PCR reactions were analyzed on 1% agarose gels stained with ethidium 
bromide. Quantification was performed by densitometric scanning of the gel 
and the amounts of amplified target cDNAs were calculated from their 
respective standard curves and normalized by those for β-actin. The 
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target/competitor ratios were proved to make PCR results quantitative 
[188]. 
4.3.3 Luciferase assay 
The DNA fragment containing the sequence from -148 to -128 from the 
LTR transcription initiation site, encompassing part of the LTR transposon 
was amplified by PCR using LA Taq and GC II buffer (Takara) following the 
manufacturer’s recommendations. The 25µl reaction contained 150 ng of 
human placenta genomic DNA as the template and primers having 
restriction sites at their 5’ -ends. The resultant fragment was cloned in the 
corresponding sites of the vector pGL3 (Promega) upstream of the firefly 
luciferase coding sequence [77] and was used as the LTR promoter (pGL3-
LTR).  
For transfection, 50,000-80,000 host cells were plated 20 h in advance in 
96-well plates with 0.1 ml of culture medium. Transfection solutions were 
prepared by mixing 200 ng of test DNA (pGL3-LTR alone or 100 ng pGL3-
LTR plus 100 ng of pcDNA3-based plasmids) with 10 ng of the Renilla 
luciferase expression vector pRL-CMV (Promega Italia) in 25 μl of serum-
free medium. Twenty-five μl of serum-free medium containing 0.6 μl of 
Lipofectamine 2000 were then added to the DNA dilution, and the complete 
solution used as above reported for all other transfections. After the 
addition of 0.1 ml of standard medium, the incubation was continued for 20 
h. The cells were then washed, lysed, and assayed for luciferase activity as 
reported [77]. 
4.3.4 EMSA assays  
EMSAs were performed with the Lightshift chemiluminescence kit (Thermo 
Scientific) following the manufacturer's recommendations, but the binding 
reaction volume was scaled down to 10 μl. DNA probes biotinylated at the 
3′-end were synthesized by Eurofinsdna-MWG Operon (Ebersberg, 
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Gemany) and diluted to be 1 nM in the assay. Nuclear extracts were 
prepared as above described for western blotting and 1 μl of extract (3–4 
μg of protein) was added to each binding reaction. Anti-HNF-1 antibody 
was incubated 30 min on ice in the binding reaction before adding the 
probes. Competitors oligonucleotides were: the unlabeled oligonucleotide 
probe (self), Cdx1/2 competitor, the 24-bp deduced from the sucrase-
isomaltase promoter (SIF1) 5’-GGGTGCAATAAAACTTTATGAGTA-3’ from 
Suh et al. [181] and the consensus sequence of AP2α 5'-
GATCGAACTGACCGCCCGCGGCCCGT-3' used as an irrelevant DNA 
control. They were present in 100-fold molar excess in the incubation 
mixture, unless differently indicated. DNA/protein complexes were 
separated by 5% native PAGE, transferred to a nylon membrane, cross-
linked under UV light, and visualized with chemiluminescence as reported 
[77].  
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5.1 Detection of HNF1α/β, Cdx1/2 and B3GALT5 LTR transcript 
in colon cancer biopsies and surrounding normal mucosa  
Firstly, we determined the expression of the B3GALT5 LTR transcript by 
competitive RT-PCR, in matched pairs of biopsies representing colon 
cancers and surrounding normal mucosae (Figure 5.1).  
Figure 5.1 Quantification of B3GALT5 LTR transcript expressed in matched 
pairs of colon cancer and adjacent normal mucosa by competitive RT-PCR. 
A) RNA extracted from the biopsies was reverse transcribed, and 
normalized amounts of the resultant first-strand cDNA were mixed with the 
indicated amounts of competitor (truncated) cDNAs and subjected to PCR 
using primers specific to LTR transcript and β-actin, respectively.The target 
doublet corresponds to the alternative splicing previously reported [77]. 
Samples were not all run on the same gel, as indicated by vertical white 
spaces. B) Quantification of B3GALT5 LTR transcript: Densitometric 
scanning of bands obtained by gel images was performed to quantitate 
B3GALT5 LTR transcript. Results are the mean ± standard deviation for 
three determinations. N: normal colon mucosa; C: colon cancer. 
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As expected, owing to the strong prevalence of such transcript in these 
tissues, the results were very similar to those previously obtained 
measuring the B3GALT5 coding sequence [71, 72], which is common to all 
transcripts. Expression levels, in fact, ranged from 11 to 1 fg/pg of β-actin 
(average 3.9) in normal colon mucosae and from 0.5 fg/pg of β-actin to 
undetectable values (average 0.13) in colon cancers (Figure 5.1). Referred 
to the matched pairs, the amount of LTR transcript decreased in cancer 
from 4- to >200-folds.  
To assess the relationship between LTR transcript and candidate 
transcription factors HNF1α/β and Cdx1/2, we determined their amounts in 
nuclear protein extracted only from two normal mucosa specimens (Figure 
5.2), since we had not enough material available for extracting nuclear 
protein from the others. We detected HNF1α/β, but their amounts were not 
related to those of B3GALT5 LTR transcript. We did not find Cdx1/2 in the 
mucosa samples analyzed.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Detection of transcription factors HNF1α/β, Cdx1/2, and histone 
H3 in two normal mucosa samples and in some cell lines. Nuclear extracts 
(5-10 μg of protein) were separated by 10% SDS-PAGE and transferred to 
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a nitrocellulose membrane that was blotted with anti HNF1 antibody 
(recognizing both HNF1α and HNF1β), or anti-Cdx1, anti-Cdx2, or anti-
histone H3 antibodies followed by HRP-labeled secondary antibody and 
      u                    ,             u     “M             M      ”  
Longer exposures were necessary for Cdx1 and Cdx2 to detect a visible 
spot.  
 
5.2 Detection of HNF1α/β and Cdx1/2 in colon cancer biopsies 
and cell lines expressing different amounts of B3GALT5 LTR 
transcript 
Since we had enough material available for extracting nuclear protein from 
eight cancer biopsies but from only two normal mucosa specimens, we 
then compared cancer samples with various cell lines presenting a wide 
range of expression of the LTR transcript. Surprisingly, we found that in all 
cancer samples tested HNF1α/β were easily detected, while Cdx1/2 were 
almost undetectable, irrespective of the amount of LTR transcript 
expressed (Figure 5.3). We also found that COLO-205 and SW-1116 cells, 
expressing the highest amount of LTR transcript (about 15 and 6 fg/pg of β-
actin, respectively), expressed only HNF1α, at levels similar to those of 
samples expressing low or no LTR transcript, such as hepatoma cell lines 
Huh-7 and Hep-3B. MKN-45 and HT-29 cells expressed both HNF1α and 
HNF1β, but the transcript levels were lower than in COLO-205 or SW-1116 
cells. On the other hand, MDA-MB-361 cells expressed only HNF1β, and a 
little more LTR transcript than MKN-45 or HT-29 cells. Interestingly, the 
cells lacking HNF1α/β also lacked LTR transcript, but not vice versa. 
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Figure 5.3 Detection of transcription factors HNF1α/β and Cdx1/2 in human 
colon cancers and in cell lines expressing different amounts of B3GALT5 
LTR transcript. (A) Detection and (B) quantification of B3GALT5 LTR 
transcript by competitive RT-PCR was performed as in figure 5.1. Note the 
different amounts of B3GALT5 LTR competitor and scales used for colon 
cancer and cell lines.(C) Western blot detection of HNF1α/β, Cdx1/2 and 
histone H3, was performed as in figure 5.2. Longer exposures were 
necessary for Cdx1 and Cdx2 to detect a visible spot. 
 
Cdx1 and Cdx2 remained undetectable under reference conditions in all 
tested samples. A weak Cdx2 spot became detectable after a longer 
exposure in HCT-15 cells and in a couple of cancer biopsies expressing no 
LTR transcript at all. To assess the sensitivity of anti-Cdx antibodies, we 
analyzed the nuclear protein extracted from HEK-293T cells transfected 
with Cdx1 or Cdx2 cDNAs and found very strong signals under the 
conditions used for detection (Figure 5.4). 
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Figure 5.4 Detection of Cdx1, Cdx2 and histone H3 proteins in human 
colon cancers, some reference cell lines and in HEK-293Tcells transfected 
with Cdx1 or Cdx2 plasmids, was performed as reported in figure 5.2. 
5.3 Detection of B3GALT5 LTR transcript in cell models 
expressing various amounts of HNF1α or HNF1β 
To elucidate the specific role of transcription factors involved in the 
regulation of B3GALT5 transcription, we compared the expression levels of 
B3GALT5 LTR transcript, quantitated by competitive RT-PCR, with those of 
candidate transcription factors HNF1α/β determined by western blot. For 
this purpose, we used various cell models serving as controls in which the 
amounts of HNF1α or HNF1β were modulated either by transfection with 
their cDNA or by inhibition with shRNA. 
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5.3.1 Effect of HNF1α/β overexpression on the levels of B3GALT5 LTR 
transcript  
To better assess the role of HNF1α/β, we planned to overexpress such 
factors in a suitable cell model. First, we determined the expression levels 
of HNF1α/β transcripts in cell lines not expressing the protein by Western 
blotting, such as HCT-15 and HuCC-T1 cells (Figure 5.5). 
Figure 5.5 Expression of HNF1α/β transcripts in various cell lines. Detection 
(lower segments) and quantification (upper segments) of HNF1α/β 
transcripts by competitive RT-PCR was performed and presented as in 
figure 5.1. β-actine samples for cDNA normalization are those presented in 
figure 5.3 
 
Surprisingly, we found that both lines expressed HNF1β transcript at 
remarkable levels. We thus extended the analysis to many other cell lines, 
and found that HNF1β RNA was commonly expressed even in cells where 
the protein is undetectable by Western blotting (Figure 5.5), suggesting a 
crucial post-transcriptional regulation of the gene. This phenomenon was 
not evident in the case of HNF1α (Figure 5.5). The breast cancer cell line 
MDA-MB-231, lacking both HNF1α/β transcripts, was thus chosen for 
transfection experiments.  
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Figure 5.6 Effect of HNF1α/β over-expression on the levels of B3GALT5 
LTR transcript. MDA-MB-231 cells, not expressing either HNF1α or HNF1β, 
were transfected with either factor and the clones were screened by 
Western blotting with anti-HNF1 antibody. RNA and nuclear proteins were 
extracted from positive clones and used for B3GALT5 LTR transcript 
quantification, and HNF1α/β detection, as reported in previous figures. A 
mock-transfected clone, obtained using the resistance plasmid mixed with 
pcDNA3 vector alone, was used as control. Huh-7, expressing high levels 
of HNF1α but not LTR transcript, and MDA-MB-361 cells, expressing 
HNF1β only and moderate amount of LTR transcript, were also used as 
references 
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The obtained clones, analyzed by Western blotting (Figure 5.6), were found 
to express varied but rather high levels of HNF1α, compared with Huh-7 
cells, and varied but low levels of HNF1β, compared with MDA-MB-361 
cells. B3GALT5 LTR transcript became detectable, although at low levels, 
in all the clones expressing either HNF1α or HNF1β (Figure 5.6). The 
amount of LTR transcript in fact ranged from 0.05 to 0.5 fg/pg of β-actin. 
However, even a weak expression of HNF1β was able to turn on 
transcription of LTR mRNA. In particular, clones β-1 and α-4 expressed 
similar levels of LTR transcript, while the amount of HNF1β in the former 
was much lower than that of HNF1α in the latter (Figure 5.6). 
Notwithstanding the low levels of HNF1β protein in the clones, the 
corresponding amount of transcript was very high, the highest detected 
among tested cells (Figure 5.7), confirming that regulation of the HNF1β 
gene is largely post-transcriptional. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 Expression of HNF1β transcripts in various cell lines and clones. 
Detection (lower segments) and quantification (upper segments) of HNF1β 
transcripts by competitive RT-PCR was performed and presented as in 
figure 5.1. β-actin samples for cDNA normalization are those presented in 
figure 5.3 
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5.3.2 Effect of HNF1α/β silencing on the levels of B3GALT5 LTR 
transcript  
To focus on the role of HNF1β, we silenced HNF1α in MKN-45 cells, which 
express both factors, and HNF1β in MDA-MB-361, which express HNF1β 
only. Using plasmids encoding shRNAs targeting either factor, we found 
that gene silencing was lost after prolonged cell replications (over 4 weeks). 
Nevertheless, we obtained a transient but strong reduction of expression of 
HNF1α in MKN-45 cells (Figure 5.8 upper panel) and of HNF1β in MDA-
MB-361 cells (Figure 5.9, upper panel), respectively.  
 
 
 
 
 
 
 
 
 
 
Figure 5.8 Effect of HNF1α silencing on MKN-45 cells on the levels of 
B3GALT5 LTR transcript. MKN-45 cells, expressing both HNF1α and 
HNF1β, as well as B3GALT5 LTR transcript, were transfected with pLKO 
plasmid bearing a shRNA sequence specifically targeting HNF1α. Individual 
clones resistant to puromycin selection were allowed to grow for a total of 3 
weeks and the obtained cells were used for Western blot analysis and RNA 
          ,             u     “M             M      ”                  was 
prepared in parallel transfecting cells with the empty pLKO vector. Western 
blotting (upper panel) and competitive RT-PCR analyses (lower panel) 
were then performed as reported in previous figures. Detection of HNF1β 
was used as internal reference to evaluate HNF1α silencing and re-
expression. 
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Figure 5.9 Effect of HNF1β silencing on MDA-MB-361 cells on the levels of 
B3GALT5 LTR transcript. MDA-MB-361 cells, expressing HNF1β only, as 
well as B3GALT5 LTR transcript, were transfected with pLKO plasmid 
bearing a shRNA sequence specifically targeting HNF1β. Individual clones 
resistant to puromycin selection were allowed to grow for a total of 3 weeks 
and the obtained cells were used for Western blot analysis, RNA extraction, 
            u     “M             M      ”                  w               
parallel transfecting cells with the empty pLKO vector. Western blotting 
(upper panel) and competitive RT-PCR analyses (lower panel) were then 
performed as reported in previous figures. Detection of histone H3 was 
used as internal reference to evaluate HNF1β silencing and re-expression. 
 
Silencing of HNF1α in MKN-45 cells had no effect on LTR transcript levels 
(Figure 5.8, lower panel), while the silencing of HNF1 β in MDA-MB-361 
cells was accompanied by a dramatic reduction of the transcript (Figure 
5.9, lower panel). After longer times following transfection, recovery of 
HNF1α expression in MKN-45 cells did not affect LTR transcript levels, 
while recovery of HNF1β expression in MDA-MB-361 cells restored the 
amount of the transcript. These data indicate that HNF1α and HNF1β play 
an interchangeable and not cumulative role, and suggested that, although 
necessary for B3GALT5 transcription, they are not sufficient to explain 
transcript modulation. 
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5.4 Effect of TSA and 5AZA treatment on the expression of 
B3GALT5 LTR transcript 
To remove potential epigenetic constraints, we performed TSA and 5AZA 
treatments, starting with MKN-45 cells since they were found to be 
sensitive to such treatments in the case of the native B3GALT5 transcript 
[78].  
 
Figure 5.10 Effect of TSA and 5AZA treatment on the expression of 
B3GALT5 LTR transcript in cultured cells. A) MKN-45 cells were treated 
with various amounts of histone deacetylase inhibitor TSA. B) MKN- 45 and 
COLO-205 cells were treated with various amounts of DNA 
methyltransferase inhibitor 5AZA for different times, as detailed under 
“M             M      ”  I  b          ,               qu                
B3GALT5 LTR transcript by competitive RT-PCR were performed as in 
previous figures. Treatments were performed in duplicate. At the end of the 
treatments, cells were harvested, washed with PBS, and processed to 
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extract RNA and nuclear protein from the same cell suspension. Results 
are the mean ± standard deviation for two determinations performed on 
each duplicate. C) Nuclear protein extracted from representative data-
points were submitted to Western blot analysis as reported in previous 
figures. 
 
We found that TSA treatment (Figure 5.10A) had no effect on the LTR 
transcript, while 5AZA, surprisingly, strongly impaired expression (Fig. 
5.10B). We repeated the treatment on COLO-205 cells, since they express 
LTR transcript at the highest levels found, and obtained similar results 
(Figure 5.10B). In fact, even in these cells 5AZA treatment impaired LTR 
expression in a dose- and time-dependent manner. In both treated cell lines 
B3GALT5 LTR transcript dropped down to the levels measured in some 
colon cancer biopsies or HNF1α/β-transfected MDA-MB-231 clones, while 
the levels of HNF1 proteins remained almost unaffected (Figure 5.10C). 
Since the 650-bp long LTR transposon contains only seven dispersed CG 
pairs, and no CpG island is present in the proximal sequences, this result 
suggests that the regulatory effect of methylation resides outside and far 
from the LTR promoter.  
5.5 In vitro evaluation of the B3GALT5 promoter 
To confirm the hypothesis that the B3GALT5 LTR promoter although 
necessary is unable to regulate transcription per se, we performed 
luciferase assays with a reporter plasmid in which luciferase is placed 
under the control of the LTR sequence, and EMSAs using the LTR 
sequence as a probe. Taking advantage of the availability of cell lines and 
clones showing various combinations of the expression levels of the 
B3GALT5 LTR transcript and HNF1α/β proteins, we used them as the host 
cells for transfecting the LTR/luciferase plasmid or as the sources for 
extracting nuclear protein to be tested with the LTR probe by EMSA. 
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5.5.1 Evaluation of the activation properties of B3GALT5 LTR 
promoter by luciferase assays 
The results of luciferase activity promoted by B3GALT5 LTR promoter are 
show in figure 5.11. The pGL3 vector carrying the sequence -148-28 from 
the transcription initiation site of B3GALT5 LTR mRNA and firefly luciferase 
gene (pGL3-LTR), was transfected together with a Renilla luciferase 
reporter expression plasmid in various cell lines expressing different 
amounts of HNF1α/β and B3GALT5 LTR transcript. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11 Luciferase activity assay of B3GALT5 LTR promoter in various 
host cells. The sequence -148-28 from the transcription initiation site of 
B3GALT5 LTR mRNA, was cloned in the pGL3 vector carrying the firefly 
luciferase gene (pGL3-LTR), and transfected together with a Renilla 
luciferase reporter expression plasmid. Host cells were cell lines or clones 
expressing different amounts of HNF1α/β and B3GALT5 LTR transcript 
used in previous experiments. pGL3-control vector, bearing the SV40 
promoter, and pGL3-basic vector, lacking any promoter sequence, were 
also transfected for normalization and control. Values are the means ± 
standard variations for two experiments in triplicate. 
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By luciferase reporter assays the highest activity was found in MKN-45 
cells, expressing high levels of both HNF1α and HNF1β and moderate 
levels of LTR transcript, followed by Huh-7 cells and MDA-MB-231 clone α-
1, which expressed high levels of HNF1α only and no or low LTR 
transcripts. Conversely, much lower luciferase activity was detected in SW-
1116 cells, expressing high levels of transcript and moderate levels of 
HNF1α. In MDA-MB-361 cells expressing moderate levels of transcript but 
low HNF1β alone, luciferase activity was minimal, and almost undetectable 
in MDA-MB- 231 clone β-1, which expresses minimal amounts of both LTR 
transcript and HNF1β.  
We also transfected HEK-293T cells with pGL3-LTR and Renilla luciferase 
plasmids in the presence of transcription factor cDNAs cloned in the 
pcDNA3 vector (Figure 5.12). HEK-293T cells lack expression of HNF1α/β 
and Cdx1/2, and are able to replicate plasmids with the SV40 origin of 
replication (as pcDNA3). Addition of each plasmid coding HNF1α/β or 
Cdx1/2 enhanced luciferase activity, with preference for HNF1α followed by 
HNF1β and Cdx2, while Cdx1 was less effective. 
 
 
 
 
 
 
 
 
 
 
Figure 5.12 Luciferase activity assay of B3GALT5 LTR promoter co-
transfected with the candidate transcription factors. pGL3-LTR and Renilla 
luciferase plasmids were mixed with expression plasmids having the coding 
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region of transcription factors cloned in the pcDNA3 vector, which bears the 
SV40 origin of replication and were transfected into HEK-293T cells. Firefly 
luciferase activity was measured 24 h later and expressed relative to the 
Renilla luciferase activity determined for each sample. Transfection with 
pGL3-LTR and Renilla luciferase plasmids mixed with pcDNA3 vector alone 
was performed as control. Values are the means ± standard variations for 
two experiments in triplicate. 
 
5.5.2 Evaluation of the binding properties of B3GALT5 LTR promoter 
by EMSA assays 
By EMSA, we found that the LTR sequence, when used as a probe, formed 
one specific complex plus one or two other non-specific complexes (Figure 
5.13). The one specific complex was the most retarded and appeared as a 
doublet, corresponding to HNF1α/β binding. In fact, it was found only with 
nuclear protein extracted from cell lines expressing HNF1α/β, was affected 
by anti-HNF1 antibody, and was competed out by an excess of the 
unlabeled probe sequence (Figure 5.13A). Such a complex was also 
evident with nuclear proteins extracted from cells expressing very low to 
undetectable levels of LTR transcript but very high levels of HNF1α, such 
as Huh-7, Hep-3B, and MDA-MB-231 clones α-1 or α-3. The complex was 
detectable but much less evident with the protein extracted from MDA-MB-
361 cells, expressing moderate levels of LTR transcript and low levels of 
HNF1β, and undetectable with MDA-MB-231 clone β-1, expressing very 
low levels of both. The other complexes were not competed out by the 
unlabeled probe, and should be considered non-specific (Fig. 5.13B). 
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Figure 5.13 Characterization of the binding properties of B3GALT5 LTR 
promoter using cell lines or clones expressing different amounts of 
HNF1α/β and B3GALT5 LTR transcript. EMSAs were performed incubating 
a biotinylated oligonucleotide probe (nucleotides -151-112 calculated from 
the transcription initiation site of B3GALT5 LTR mRNA) with the nuclear 
protein extracted from the mentioned cell lines or clones.  
 
In particular, the complex migrating as the less-retarded doublet was 
formed by almost any nuclear extract, including those prepared from cells 
not expressing B3GALT5 LTR and unable to drive luciferase activity upon 
transfection with the LTR construct. It migrated much faster than true Cdx1 
or Cdx2 complexes formed by the same LTR probe with authentic Cdx1 or 
Cdx2 protein, and was not competed out by the SIF1 sequence, as 
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occurred with the true Cdx1 or Cdx2 complexes formed by recombinant 
factors (Figure 5.14). Although the LTR promoter was able to bind Cdx1/2 
in vitro, taken together the data indicate that the HNF1 binding site is the 
only functional sequence brought by the insertion of the LTR transposon. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14 Characterization of the binding properties of B3GALT5 LTR 
promoter using HEK-293T cells expressing recombinant transcription 
factors Cdx1 or Cdx2 and SW-1116 cells as control. EMSAs were 
performed incubating a biotinylated oligonucleotide probe (nucleotides -
151-112 calculated from the transcription initiation site of B3GALT5 LTR 
mRNA) with the nuclear protein extracted from the mentioned cell lines or 
clones. 
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Literature data [71] reported that transcriptional regulation of B3GALT5 
gene was under the cooperative control of HNF1 and Cdx as for other 
genes specifically expressed in intestine like sucrose-isomaltase [182], 
lactase-phlorizin hydrolase (LPH) [189] and claudin-2 [190]. Isshiki et al. 
[71], in their study attributed a positive role for HNF1α and Cdx2 in 
regulating B3GALT5 transcript whereas HNF1β and Cdx1 did not affect the 
levels of the transcript. Conversely, we observed that Cdx1/2 are not 
involved, while HNF1α or HNF1β are necessary to activate the B3GALT5 
LTR promoter, playing an interchangeable and not cumulative role, but they 
are unable to modulate transcription, which instead depends on distal 
regulatory element(s) active when methylated, and which are unknown at 
present. 
The complex role played by HNF1 was defined by several lines of 
evidence. First of all, in any cell line lacking both HNF1α and HNF1β the 
B3GALT5 LTR transcript was always undetectable; moreover, transfection 
of one of these cells with either HNF1α or HNF1β cDNA induced LTR 
transcription. In addition, shRNA-mediated silencing of HNF1β in cells 
expressing only HNF1β, strongly impaired LTR expression. These results 
clearly indicate that HNF1 is necessary for transcription. Since the 
transcript was detected in cell lines and clones expressing either HNF1α or 
HNF1β alone, and shRNA-mediated silencing of HNF1α in cells expressing 
both HNF1α and HNF1β does not affect LTR expression, the two forms 
appear to not be cooperative, but interchangeable, as reported in the gut 
[191] but not in the kidney [176]. HNF1α and HNF1β bind DNA with the 
same sequence specificity and can form homo- or heterodimers [176]. The 
fact that these two genes share the same DNA binding specificity and 
overlapping expression pattern, together with their ability to form 
heterodimers, suggests that these proteins could play complementary 
roles. However, HNF1α seems to be a more potent transactivator than is 
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HNF1β in transient transfection assays [176], as we also corroborate with 
our study. 
On the other hand, the expression levels of either HNF1 form, or of both 
forms when expressed together, cannot explain the wide expression range 
of the LTR transcript. In fact, we detected comparable amounts of HNF1 in 
COLO-205 or SW-1116 cells, which expressed the highest levels of LTR 
transcript, and in cells, clones or colon cancer biopsies which expressed 10 
or 100-fold less, or even undetectable, LTR transcript. This evidence 
prompts the question about what other factor or mechanism affects 
B3GALT5 LTR transcription and is responsible for cancer down-regulation.  
We found that Cdx1/2 were not involved, although they were able to bind 
and activate the LTR promoter in vitro. In fact, the amounts of Cdx1/2 in 
cells or tissues expressing B3GALT5 LTR transcript were negligible and the 
few samples expressing detectable amounts of Cdx2 (HCT-15 cells and 
colon cancer biopsies 1 and 2) lacked B3GALT5 LTR transcript. Moreover, 
nuclear protein extracted from cells expressing the transcript never formed 
Cdx1/2 complexes in EMSA. The less-retarded doublet detected by EMSA 
with the LTR probe, previously proposed to depend on Cdx1/2 binding [71] 
did not behave as true Cdx1/2 complexes, but was found to be a non-
specific artifact, formed by any nuclear protein extract, including those from 
cells not expressing the transcript at all. Altogether, these data indicate that 
the HNF1 binding site is the only functional part of the LTR promoter, and 
that no other binding sites, for stimulatory or inhibitory factors, including 
Cdx1/2, are physiologically relevant. 
Conversely, DNA demethylation obtained through 5AZA treatment of cells 
expressing the B3GALT5 LTR transcript reproduced in vitro the down-
regulation of the transcript observed among cell lines and cancer biopsies 
in vivo. In fact, in treated cells, the levels of B3GALT5 LTR transcript 
decreased from 3-10 to less than 0.2 fg/pg β-actin, while the amounts of 
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HNF1 remained almost unchanged. Since LTR transposon contain only 
seven CG pairs (Figure 6.1) and proximal sequences do not contain CpG 
islands, we conclude that methylation-sensitive DNA sequences represent 
element(s) involved in transcriptional regulation residing outside the LTR 
sequence, probably distant from the promoter.  
 
 
 
 
 
 
 
Figure 6.1 Nucleotide sequence of B3GALT5 LTR transposon. Exon 1 of 
B3GALT5, framed by a red line; CpG dinucleotides, green boxes and 
putative HNF1/Cdx binding site, yellow box. 
 
Alignment of the LTR sequence and the whole B3GALT5 gene in the 
context of chromosome 21 revealed a single typical promoter-associated 
CpG island, already characterized in detail and responsible for regulating 
transcription of the native B3GALT5 mRNA [78]. In addition, a number of 
very short CpG islands were detected, one in an intron and the others in 
the intergenic regions (Figure 6.2). Unfortunately, due to the extremely high 
homology (> 98%) of this human sequence with that of the other primates 
sharing the LTR transposon, no prediction can be made in silico about the 
relevance of any of such island. Alternatively, we could suppose that the 
region involved is over 0.1 Mbp away from the LTR sequence. 
We thus propose a model of B3GALT5 transcription predicting that a 
distant DNA region, methylated in normal colon mucosa and cell lines such 
as COLO-205 or SW-1116, is demethylated in colon cancer, in several cell 
lines and even in other tissues still expressing HNF1; the degree of 
TGTGATGGTT ACTTTTAGGT GTCAACTTGG CTGGATTAAT AAATACCTAG AGAACTGGTA 
AAGCATTATT TCTGGGTGTG TTTGTGAAGG TGTTTCCAGA GGAGATTGGC TGTGAGTCAG 
TGGGCTGAGT GGGGAGGAGC TGCCCTCCAT GTGGGCAGGC ACCATCCATT GACTGGGCCC 
AGATAGAACA AGAAGGCAGA AGAAATGTGA ATTCCTCTTT CTCTGCTGGA GCTGGGATAT 
TCTTCTTCTC CTGCCCTTGG ACATCAGAGC TGCAGGCTCT CTGGCCTTTG GACCCGAGGA 
TTTATACCAA GCAGGTTTCT GGGTTCTCAG GCCTTTGGCC TTGGACTGAT AGTTACACCA 
TTGGCATATC TGGTTCTGAG GCTCTTGGTC TTGGACTGAG CCACACTCCT GGCATCCCAG 
CGTCTCCAGC TTGCATGGCC TGTCACGGTA TTTCCCAACC TCCGTAATCA CGCTAGCCAA 
TTCTTCTAAG AAATTTCTTC TCATCTATCT GTCTGTCTAT CTATCTATCT GTCTACCTAC 
CGACTTACCT ACCTACCTGC CTATCTATCT TTTGATTAAT CTACCTATCA ATCTTTCTAT 
CTATCCATAA CCTGTTGATT CGATCTCTCT AGAGAACCCT GACTAATACA 
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demethylation downregulates transcription even to complete silencing, as in 
Hep-3B and Huh-7 cells. 
DNA hypomethylation was indeed the first epigenetic abnormality detected 
in human cancers about 30 years ago [192]. However, it received much 
less attention in the last decade than the opposite modification, 
hypermethylation, frequently associated with silencing of tumor-suppressor 
and other genes. Only recently, high-resolution genome-wide analyses 
revealed an independent and relevant role of hypomethylation in cancer 
formation and progression [141, 193]. Among various DNA sequences 
affected by cancer-associated hypomethylation, transcription control 
elements appeared to be of special interest. In particular, it was found that 
genes associated with hypermethylated distant control elements are more 
frequently downregulated in cancer [167]. 
No information about the nature, exact location, or mechanism of action of 
such distant sequence is available for B3GALT5 transcription at present. It 
may represent a typical CpG island, or a “shore” as recently proposed [147] 
(see after), a non-CpG methylation site [150] or instead include stretches of 
CpG dinucleotides shorter than CpG islands associated with promoters.  
 
Figure 6.2 CpG islands detected in the context of the B3GALT5 gene. The 
genomic sequence of chromosome 21 (0.26 Mbp) encompassing B3GALT5 
and intergenic regions was analyzed with EMBOSS Cpgplot software 
(EMBL), with the following parameters: observed:expected ratio >0.6, C+G 
>50%, and minimum length, 120 bp. One CpG island was present near 
exon 1A, which regulates the cognate promoter [78]. Several shorter 
stretches of CpG dinucleotides were instead detectable in the intergenic 
regions. 
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Many studies on cancer methylation have assumed that functionally 
important DNA methylation occurs in promoters and that most DNA 
methylation changes in cancer occur in CpG islands. However, it was  
proved that many methylation alterations in colon cancer do not occur in 
promoters or in CpG islands, but in sequences up to 2 kb distant termed 
‘CpG island shores’ [147]. CpG island shore methylation is strongly related 
to gene expression, and it is highly conserved in mouse, discriminating 
tissue types regardless of species of origin.  
Particularly, methylation of stretches of CpG dinucleotides, as those 
present in the intergenic regions of B3GALT5, is emerging as a relevant 
aspect of transcriptional control [157], being responsible for recruitment of 
alternative promoters, regulation of non-coding RNA synthesis, or 
modulation of enhancer activity. In particular, hypomethylation of enhancer 
sequences is reported to negatively regulate transcription in cancer and 
during tissue differentiation [157]. The occurrence of distal regulatory 
elements binding transcription factors in a methylation-dependent manner 
was recently reported in breast cancer [167]. Other types of genome-wide 
analyses predicted that HNF1 is able to play such a role in the kidney [194] 
and in the liver [195]. B3GALT5 transcription thus represents a promising 
model to address such novel issues, since hypomethylation of distant 
sequences, acting on the LTR transcript, and promoter hypermethylation, 
acting on the native transcript [78], cooperate on one gene to obtain full 
cancer-associated silencing.  
It is generally accepted that transposable elements are common targets of 
DNA methylation, and that their transcription is increased in 
hypomethylated cellular environments [103, 196]. It is striking that the LTR-
driven transcripts of many mammalian genes are expressed early in 
development, in tumors, and in tissues such as the placenta, where the 
level of DNA methylation is generally lower [87, 127, 196]. This suggests 
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that they may be regulated in part by DNA methylation. In contrast, 
B3GALT5 LTR promoter is the first described example of LTR promoter 
having a positive correlation between promoter expression and DNA 
methylation. 
Our present findings also contribute to better understanding of the 
mechanism of evolutionary stabilization of the LTR transposon with respect 
to the models hypothesized for other mobile elements [197]. In fact, 
previous evidence suggested that the transcription factors binding sites in 
the B3GALT5 LTR promoter were present in the original consensus 
sequence for this class of LTRs, maintaining the functional roles [76]. Such 
hypothesis is based on the sequence comparison between the specific LTR 
copy, the LTR consensus sequence, and insertions in other primates. It 
was proposed a model by which the LTR promoter was already active at 
the time of insertion [76] and may have taken advantage of the analogous 
sequence present in the type B promoter, which is much less active due to 
its opposite orientation [77]. Now we propose that effective interaction with 
a distant element played a crucial stabilizing effect, probably due to the 
precise localization of insertion, which in turn allowed not only stronger 
HNF1-associated expression, but even the finest tissue specificity obtained 
through the overlapping epigenetic control operated by the distal element. 
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These results appear self-consistent concerning the interchangeable but 
not cumulative role of HNF1α and HNF1β in the regulation of B3GALT5 
transcription. HNF1α/β are necessary but not sufficient to drive expression 
of LTR transcript, although they are both able to bind and activate the LTR 
promoter in vitro. They are not immediately responsible for cancer down-
regulation, which instead depends on distal regulatory elements active 
when methylated and unknown at present. Moreover, the HNF1 binding site 
is the only functionally relevant binding site present in the LTR promoter 
since the Cdx1/2 binding site do not appear involved.  
We also propose that the successful insertion and activation of B3GALT5 
LTR promoter during evolution depended on its HNF1 binding site as well 
as on the distal regulatory element(s) sensitive to methylation, perhaps  
playing a positional role. The data thus suggest the existence of an 
unprecedented regulatory mechanism involving methylation of distal DNA 
elements as a requirement for transcriptional activation. Since the LTR 
retrotransposon is present in some primates only, which shares over 95% 
identity in the flanking DNA regions, no information from evolutionary 
conserved sequences is available. As future strategies, we are trying to 
recognize potential CpG islands and/or shores in the flanking regions (+/- 
100 kBp from the LTR sequence) with the aim to perform bisulfite 
sequencing using model cell lines as COLO-205 (expected 
hypermethylated) and MDA-MB-231 (expected hypomethylated). We are 
also trying to determine the potential enhancer activity of selected distal 
DNA region through cloning in luciferase reporter vectors and assaying 
upon transfection in model cell lines.  
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